Startups
The company’s current portfolio includes Castle Creek Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the replicable Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation.
Overview
Location
United States, Illinois, Chicago
Employees
11-50
Phone
+1 312-847-1350
Founded date
2010
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 6, 2022 | As part of broader gene therapy ambitions, Takeda links up again with a small Chicago biotech | Takeda is inking gene therapy deals left and right. This time, it’s partnering for a second time with Chicago-based protein maker Evozyne. After lining up collaborations with Code Biotherapeutics, Poseida Therapeuti... |
| Sep 14, 2021 | Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder | CHICAGO, Sept. 14, 2021 /PRNewswire/ -- Emalex Biosciences, Inc. ("Emalex"), a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, is seeking people who s... |
| Aug 20, 2019 | Paragon Biosciences Forms Paragon Health Capital | Paragon Biosciences, LLC, a Chicago, IL-based life science firm that invests in, builds, and advises bioscience companies, has formed Paragon Health Capital, LLC. Led by Brian Friedman, CEO, Paragon Health Capital is a private equity firm t... |
| Jul 17, 2019 | Paragon Biosciences launches Qlarity Imaging to advance QuantX, the first AI breast cancer diagnostic tool to get FDA clearance | Paragon Biosciences, a global healthcare company committed to accelerating biomedical research, is announcing the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded to harness the value of artificial intelligenc... |
| Oct 9, 2017 | Harmony Biosciences Raises $270M | Biopharmaceutical company Harmony Biosciences, LLC, a member of the Paragon Biosciences (Paragon) corporate family, today announced it has acquired the exclusive US right to develop, register and market the drug pitolisant from French compa... |
| Paragon Biosciences | “Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.” |
Reviews 0
FAQ about Paragon Biosciences
When was Paragon Biosciences founded?
Paragon Biosciences was founded in 2010.
What has the press written about Paragon Biosciences?
Parsers VC has collected 7 articles mentioning Paragon Biosciences, among them “As part of broader gene therapy ambitions, Takeda links up again with a small Chicago biotech” (Apr 6, 2022) and “Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder” (Sep 14, 2021).
Is Paragon Biosciences still active?
Yes, Paragon Biosciences is active; its latest activity on Parsers VC dates from Aug 29, 2024.